Novel mutation in the CMV UL97 gene associated with resistance to ganciclovir therapy

Transplantation

Volumn 67, Issue 5, 1999, Pages 755-757

  Mendez, J C ^b   Sia, I G ^b   Tau, K R ^b   Espy, M J ^b   Smith, T F ^b   Chou, S ^b   Paya, C V ^a  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR;

ADULT; ARTICLE; CASE REPORT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; GENE AMPLIFICATION; HUMAN; KIDNEY TRANSPLANTATION; NONHUMAN; POLYMERASE CHAIN REACTION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; VIRUS GENE; VIRUS MUTATION; VIRUS REPLICATION;

EID: 0033559061     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199903150-00020     Document Type: Article

References (13)

1. Peterson PK, Balfour HH Jr, Marker SC, Fryd DS, Howard RJ, Simmons RL. Cytomegalovirus disease in renal allograft recipients: a prospective study of the clinical features, risk factors and impact on renal transplantation. Medicine (Baltimore) 1980; 59: 283.
2. Patel R, Snydman DR, Rubin RH, et al. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 1996; 61: 1279.
3. Erice A, Chou S, Biron KK, Stanat SC, Balfour HH Jr, Jordan MC. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 1989; 320: 289.
4. Chou S, Erice A, Jordan MC, et al. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J Infect Dis 1995; 171: 576.
5. Espy MJ, Patel R, Paya CV, and Smith TF. Comparison of three methods for the extraction of viral nucleic acids from blood cultures. J Clin Microbiol 1995; 33: 41.
6. Sandhu GS, Kline BC, Stockman L, et al. Molecular probes for diagnosis of fungal infections. J Clin Microbiol 1995; 33: 2913.
7. Drew WL, Miner RC, Busch DF, et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus in immunocompromised patients. J Infect Dis 1991; 163: 716.
8. Rosen HR, Benner KG, Flora KD, et al. Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation. Transplantation 1997; 63: 476.
9. Chou S, Guentzel S, Michels KR, Miner RC, Drew WL. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J Infect Dis 1995; 172: 239.
10. Chou S, Marousek G, Guentzel S, et al. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J Infect Dis 1997; 176: 786.
11. Baldanti F, Underwood MR, Talarico CL, et al. The Cys607->Tyr change in the UL97 phosphotransferase confers ganciclovir resistance to two human cytomegalovirus strains recovered from two immunocompromised patients. Antimicrob Agents Chemother 1998; 42: 444.
12. Chee MS, Lawrence GL, Barrell BG. Alpha-, beta-and gamma-herpesviruses encode a putative phosphotransferase. J Gen Virol 1989; 70: 1151.
13. Michel D, Pavic I, Zimmermann A, et al. The UL97 gene product of human cytomegalovirus is an early-late protein with a nuclear localization but is not a nucleoside kinase. J Virol 1996; 70: 6340.